NIAID Archives
Cellular antiviral defenses
Jul. 23, 2020—A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial
Jul. 15, 2020—In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
“Nur” target may aid arthritis treatment
Jul. 13, 2020—Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.
Recurrent UTIs linked to hidden reservoir
Jul. 9, 2020—Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.
C. diff captures blood cell cofactor to build defensive shield
Jun. 10, 2020—Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.
Study explores how staph bacteria can survive in bone
Jun. 3, 2020—A comprehensive evaluation of the metabolic pathways that support Staphylococcus aureus (“staph”) growth during invasive bone infections could offer new targets for treatment.
Antibodies eye Pacific Island “fever”
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
The adaptable anthrax bacterium
May. 14, 2020—Vanderbilt researchers discover how anthrax bacterium defends itself against structural damage and resists the toxicity of the antimicrobial drug targocil.
Study to determine rate of novel coronavirus infection in U.S. children
May. 12, 2020—Researchers at Vanderbilt University Medical Center (VUMC) are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families.
Antibody finding raises hopes for Marburg, COVID-19 treatments
Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.
